Anzeige
Meldung des Tages: Ist das DIE Rohstoff-Story des Jahres?

Spyre Therapeutics Aktie News

Aktie
WKN:  A3D4LY ISIN:  US00773J2024 US-Symbol:  SYRE Branche:  Biotechnologie Land:  USA
28,40 €
-0,60 €
-2,07%
20.01.26
Depot/Watchlist
Marktkapitalisierung *
1,01 Mrd. €
Streubesitz
9,00%
KGV
-15,43
Index-Zuordnung
-

Spyre Therapeutics News

17.06.25 - PR Newswire
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-​Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver ...
16.06.25 - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-...
06.06.25 - PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire
28.05.25 - PR Newswire
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Spyre Therapeutics to Participate in Upcoming June Investor Conferences PR Newswire
08.05.25 - PR Newswire
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
05.05.25 - PR Newswire
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 ...
02.05.25 - PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire
04.04.25 - PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire
27.03.25 - PR Newswire
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody PR Newswire
07.03.25 - PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire
27.02.25 - PR Newswire
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update PR Newswire
25.02.25 - PR Newswire
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics to Participate in Upcoming March Investor Conferences PR Newswire
19.02.25 - PR Newswire
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation PR Newswire
07.02.25 - PR Newswire
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards PR Newswire
04.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PR Newswire
28.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE PR Newswire

Newssuche

Videos

newspaper
22.01.26 -33,33%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »